The Galien Foundation has revealed its latest nominees for the 2021 Prix Galien USA Award highlighting innovations in biotechnology, pharmaceutical agents, medical technology and digital health products. Entrants to the competition must have received FDA approval within the past five years and demonstrate exceptional therapeutic potential. The Galien Foundation does not use financial data to…
Roche’s tumor-agnostic therapy Rozlytrek gaining traction
ROZLYTREK from Roche‘s Genentech division is FDA-indicated for adult patients with metastatic non-small cell lung cancer whose tumors are ROS1-positive. In addition, it is indicated for adults and children 12 and older with solid tumors. The latter indication requires that the tumors have a neurotrophic tyrosine receptor kinase gene fusion without a known acquired resistance mutation. Other requirements…